Compare Marqeta Inc (MQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marqeta Inc trades at $17.22 (market cap $1.85B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Marqeta Inc is the larger of the two by market cap, and Marqeta Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MQ | RXRX | |
|---|---|---|
Market Cap | $1.85B | $1.53B |
Sector | Technology | Health |
52-Week High | $27.32 | $6.79 |
52-Week Low | $15.04 | $2.84 |
Enterprise Value | $1.15B | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
